Compare · AZTR vs NVO
AZTR vs NVO
Side-by-side comparison of Azitra Inc (AZTR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZTR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 40077.7x AZTR ($4.3M).
- Over the past year, AZTR is down 89.9% and NVO is down 28.6% - NVO leads by 61.3 points.
- AZTR has been more active in the news (5 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for AZTR).
- Company
- Azitra Inc
- Novo Nordisk A/S
- Price
- $0.07-39.80%
- $38.82-1.05%
- Market cap
- $4.3M
- $173.66B
- 1M return
- -60.08%
- -10.14%
- 1Y return
- -89.87%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2023
- News (4w)
- 5
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AZTR
- Azitra, Inc. Announces Reverse Stock Split
- Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
- Azitra Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 424B5 filed by Azitra Inc
- Azitra Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
- SEC Form SCHEDULE 13G filed by Azitra Inc
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank